Management of bleeding and invasive procedures in patients treated with anti-factor XI(a) anticoagulants: proposals from the French Working Group on Perioperative Haemostasis and French Society of Thrombosis and Haemostasis.

Fiche publication

Date publication

mars 2025

Journal

Research and practice in thrombosis and haemostasis

Auteurs

Membres identifiés du Cancéropôle Est :
Pr NGUYEN Philippe

Tous les auteurs :
Godier A, Lasne D, Martin AC, Pernod G, Albaladejo P, De Maistre E, Fontana P, Lecompte T, Le Gal G, Levy JH, Mazighi M, Mullier F, Nguyen P, Roullet S, Schved JF, Sié P, Blais N, Gouin-Thibault I, Susen S,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40496572

Résumé

Several anti-FXI(a) agents with distinct mechanisms of action and pharmacological properties are currently under clinical development. While these anticoagulants are not yet available, there is a need to address bleeding risk management for patients already enrolled in phase III trials. These patients may face elective or unplanned invasive procedures and bleeding events in anticipation of marketing authorization.Experience from managing patients with inherited FXI deficiency, along with data from early clinical trials, suggests that the bleeding risk associated with anti-FXI(a) is likely to be low but can vary depending on the clinical situation. Anti-FXI(a) reversal options include tranexamic acid, FXI concentrates, and recombinant activated factor VII. However, these options may not always be suitable, can be expensive, and may carry a thrombotic risk.